Alnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales Concerns
Alnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales Concerns Yahoo Finance
Covered in this story
Analyst targets on Alnylam Pharmaceuticals
- Freedom Broker: $174 → $350 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ALNY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Alnylam Pharmaceuticals →Dalsna Finance is currently tracking 49 stories mentioning Alnylam Pharmaceuticals, the earliest published 16 May 2017.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.